GF-DUAL 10mg

For research use only — not for human or veterinary use.

Analytical Verification (COA)

Each batch of GF-DUAL supplied by Grail Formula undergoes independent third-party laboratory verification to confirm compound identity, assay content, purity and microbiological safety.

Analytical testing for this batch was performed by Liquilabs s.r.o. (Czechia) using validated chromatographic and spectrometric techniques.

Batch: GF082025002

Key analytical results include:

• Assay Content: 10.22 mg
• Identification – Retention Time: 0.99
• Identification – Spectrum: 997
• Purity: greater than 99.8 percent
• Bacterial Endotoxins: below 0.001 EU per mg
• Total Aerobic Microbial Count: not detected
• Total Yeast and Mold Count: not detected

Independent heavy metal screening confirmed no detectable levels of arsenic, cadmium, cobalt, lead, nickel, mercury or vanadium.

These analytical procedures ensure traceability, purity verification and laboratory-grade compound consistency.

Product Overview

GF-DUAL is a synthetic peptide frequently studied in controlled laboratory environments investigating metabolic hormone signalling and regulatory endocrine pathways.

The compound belongs to a class of incretin-related peptide analogues designed for experimental investigation of metabolic signalling systems.

This preparation contains 10 mg of high purity lyophilized peptide supplied in a sealed research vial. The lyophilization process preserves peptide stability and allows researchers to reconstitute the compound for controlled in vitro experimentation.

Because of its defined molecular structure and stable analytical profile, GF-DUAL has become a widely referenced compound in experimental metabolic signalling research models.

Compound Overview

GF-DUAL is a synthetic peptide analogue designed to interact with incretin-related signalling systems that regulate metabolic and endocrine communication pathways.

In biochemical research, incretin signalling pathways are studied for their role in glucose regulation, hormone signalling and metabolic homeostasis.

GF-DUAL has been examined in experimental models exploring how peptide analogues interact with receptor-mediated signalling systems involved in metabolic regulation.

These studies allow researchers to investigate peptide-mediated signalling networks that influence cellular metabolic processes.

Historical Background and Scientific Context

Scientific interest in incretin hormones expanded rapidly during the late twentieth and early twenty-first centuries as researchers explored hormone systems involved in metabolic regulation.

Hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) were identified as key regulators of metabolic signalling pathways.

Subsequent research led to the development of synthetic peptide analogues capable of interacting with these signalling pathways for experimental study.

GF-DUAL emerged as one such compound used in laboratory models investigating dual incretin-related signalling mechanisms and metabolic regulatory pathways.

Mechanistic Focus in Research

Within experimental laboratory environments, GF-DUAL is often studied in relation to metabolic signalling pathways and hormone-mediated regulatory systems.

Research investigations commonly explore the compound in experimental models examining:

• Incretin-related signalling pathways
• GLP-1 receptor interaction systems
• GIP receptor signalling pathways
• Metabolic hormone regulatory networks
• Peptide hormone interaction dynamics
• Intracellular metabolic signalling models
• Comparative peptide analogue research

These experimental models allow scientists to investigate molecular mechanisms involved in metabolic signalling and endocrine regulatory processes.

Research Applications

In controlled research environments, GF-DUAL may be utilised in experimental models designed to explore peptide hormone signalling and metabolic regulatory systems.

Examples of research applications include:

• Metabolic signalling pathway research
• Peptide hormone receptor studies
• Cell signalling pathway analysis
• Molecular metabolic regulation studies
• Comparative peptide analogue evaluation
• Biochemical signalling network modelling
• Controlled in vitro metabolic research

Grail Formula Quality

Every Grail Formula research compound is produced under strict quality control procedures designed to support reliable laboratory experimentation.

Each batch undergoes independent analytical testing to verify:

• Compound identity
• Assay accuracy
• Purity confirmation
• Microbial safety
• Endotoxin levels
• Heavy metal screening
• Full batch traceability

All testing is performed by independent laboratories to ensure transparent verification and reproducible research material.

Research Use Limitation

• Used solely for in vitro experiments
• Not permitted for clinical trials involving humans
• Not permitted for human or veterinary administration
• Not permitted for investigational human use

Independently verified by Liquilabs s.r.o. (Czechia)
Validated assay content 10.22 mg
Purity greater than 99.8 percent
Retention time and spectral identity confirmation
Endotoxin levels below 0.001 EU per mg
No detectable microbial contamination
No detectable heavy metals
EU shipments include bacteriostatic water
For research use only — not for human or veterinary use

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.